Clinical trial NCT02242292: Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort
Official title: A Double-blind, Placebo-controlled, Randomized, Parallel Group Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butylbromide When Used On-demand up to 7 Episodes Over a Period of 6 Weeks for the Treatment of Occasional Episodes of Self-reported Abdominal Pain, Cramping, and Discomfort Associated With Cramping in an OTC-like Study Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Colic
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-09-17
Enrollment: 527
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study to determine whether hyoscine butylbromide can provide adequate symptomatic relief of a single episode - defined as lasting not longer than 1 day - and multiple episodes of abdominal pain or discomfort associated with cramping when used as needed


Eligibility criteria: Inclusion Criteria:

1. Adult males and females 18 years of age and older
2. Have at least a 3-month self-reported history of recurrent episodic symptoms, usually lasting for 1 hour or more, of self-described abdominal pain or discomfort associated with cramping, which they routinely either have not treated or treated using Over-the-counter (OTC) medications, in which subjects suffered these symptoms at a frequency of at least twice monthly to several times weekly, but not on a daily basis. The episodes of abdominal pain or discomfort may have been associated with other symptoms of GI dysfunction, such as diarrhea, constipation, and bloating
3. Symptoms typically have a moderate or greater severity (moderate, severe, very severe) and are sufficiently bothersome to require treatment or intervention
4. Symptoms are not associated with abdominal tenderness, swelling, fever, weight loss, or passage of blood per rectum. The onset of symptoms may or may not have been associated with ingestion of food or beverages
5. The episodes of abdominal pain or discomfort may have been associated with other symptoms of GI dysfunction, such as diarrhea, cramping, constipation, and bloating
6. Subjects are required to be able to comprehend and participate in the activities required for participation in the trial, to have the ability to attend required site visits, and to be available and have the facility to participate in a daily telephone call or computer entry (using a touch-tone phone or computer IVRS entry), which served as the mechanism for diary entry, during the 6-week course of the study. Subjects were required to successfully complete an Interactive voice response system (IVRS) training session prior to entry into the study
7. All subjects completed and signed an informed consent form

Exclusion Criteria:

1. Subjects who reported having these symptoms for the first time, particularly if they were 50 years or older, as this may have been a sign of a more serious organic disease
2. Subjects with a known hypersensitivity or allergy to hyoscine butylbromide or any of the inactive ingredients
3. Subjects who are currently under a physician's care for abdominal symptoms and/or not using medication or using prescription or OTC medications prescribed by a physician to treat symptoms of abdominal pain, cramping and discomfort or taking prescription medication(s) for the treatment of Irritable bowel syndrome (IBS) (Bentyl® or other antispasmodics, Zelnorm® \[tegaserod\], Lotronex® \[alosetron\], prokinetic agents). Current physician's care was defined as the subject presently following clinician advice regarding treatment and management of the abdominal pain or discomfort associated with the cramping symptom
4. Subjects who are having symptoms of abdominal swelling, fever associated with symptoms of abdominal pain or discomfort associated with cramping, and/or experiencing passage of blood per rectum associated with symptoms of abdominal pain or discomfort associated with cramping, or who have any evidence of abdominal tenderness (or any other evidence of an acute abdomen), abdominal masses, organomegaly or any other abnormality on abdominal examination
5. Subjects with a history of colon or other GI cancer or malignancy, inflammatory bowel disease, or Crohn's disease
6. Subjects with chronic constipation
7. Subjects with myasthenia gravis or megacolon
8. Subjects who have undergone abdominal surgery within the past 2 years, having GI surgery resulting in removal of all or part of the colon, small intestine, or stomach, or having a history of GI by-pass surgery for weight reduction
9. Prior history of gallbladder removal, appendectomy, and/or surgery for peptic ulcer disease or gastroesophageal reflux disease (GERD), was not exclusionary.
10. Subjects whose major symptoms were retrosternal burning, acid reflux, acid regurgitation, or heartburn are excluded
11. Subjects using prescription anticholinergic medications or medications for the treatment of myasthenia gravis, glaucoma, or ocular hypertension are excluded
12. Subjects who were currently participating in other trials or who participated in a clinical trial within the prior 30 days are excluded
13. Women who reported being pregnant, are nursing, or who are of child-bearing potential and not using an adequate method of birth control (medication, device, abstinence, sterilization for either partner) for 30 days before enrollment and did not agree to continue using an adequate method of birth control for 30 days after completion of the trial are excluded
14. Any women of childbearing potential who have a positive serum pregnancy test are excluded
15. Post-menopausal women who have been post-menopausal for a duration of less than 2 years and did not have a hysterectomy or tubal ligation procedure are excluded
16. Subjects who have tachyarrhythmia (defined as any disturbance of the heart's rhythm, regular or irregular, resulting in a rate over 100 beats per minute) during a physical examination are excluded
17. Subjects who have been previously diagnosed with benign prostatic hyperplasia (BPH) or subjects who experienced urinary retention are excluded
18. Subjects with clinically significant cardiovascular disease in the opinion of the investigator (including hypotension, hypertension, severe coronary artery disease, congestive heart failure, angina pectoris) are excluded

Primary outcomes:
measure: Response rate in treating the first episode of abdominal pain or discomfort associated with cramping
timeFrame: within 24 hours after starting treatment
Secondary outcomes:
measure: Response rate to trial medication
timeFrame: up to day 41
measure: Assessment of Average symptom relief rated on 4-point scale
timeFrame: up to day 41
measure: Time to onset of any effect after the first tablet taken assessed on 5-point scale
timeFrame: within 24 hours after starting treatment
measure: Time to onset of any effect assessed on 5-point scale
timeFrame: up to day 41
measure: Time to obtain adequate relief after the first tablet taken assessed on 5-point scale
timeFrame: within 24 hours after starting treatment
measure: Time to obtain adequate relief assessed on 5-point scale
timeFrame: up to day 41
measure: Average time to obtain adequate relief per subject assessed on 5-point scale
timeFrame: up to day 41
measure: Average number of tablets taken to treat episodes per subject
timeFrame: up to day 41
measure: Percentage of episodes of diarrhea
timeFrame: up to day 41
measure: Percentage of bloating episodes
timeFrame: up to day 41
measure: Percentage of constipation episodes
timeFrame: up to day 41
measure: Percentage of episodes in relief of abdominal pain or discomfort associated with cramping
timeFrame: up to day 41
measure: Global Assessment of efficacy by subject on 4-point scale
timeFrame: Day 42
measure: Global Assessment of tolerability by subject on a 4-point scale
timeFrame: Day 42
measure: Global assessment of tolerability by investigator on a 4- point scale
timeFrame: Day 42
measure: Number of patients with adverse events
timeFrame: up to 42 days
measure: Number of patients with abnormal changes in laboratory parameters
timeFrame: up to 42 days
Other outcomes:
Locations:
Study officials:
References: